For the treatment of DTX‐acquired resistance, the proposed encapsulation of DTX into mucoadhesive chitosan‐coated liposomes13 could improve drug bioavailability inside and surrounding cancer cells that potentially enhance drug sensitivity via mucin‐chitosan interaction. Here, MUC5AC is linked to cancer.